Galera Therapeutics Files 8-K/A Amendment
Ticker: GRTX · Form: 8-K/A · Filed: Mar 24, 2025 · CIK: 1563577
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Galera Therapeutics amended its 8-K filing from Dec 30, 2024, with new financial docs.
AI Summary
Galera Therapeutics, Inc. filed an 8-K/A on March 24, 2025, to amend its previous 8-K filing dated December 30, 2024. This amendment pertains to financial statements and exhibits, indicating a correction or addition to previously reported information. The company is incorporated in Delaware and headquartered in Malvern, PA.
Why It Matters
This filing indicates that Galera Therapeutics is making corrections or additions to its previously filed financial statements and exhibits, which could impact the understanding of its financial position.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, likely for administrative or minor corrections, and does not appear to introduce new material risks.
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- December 30, 2024 (date) — Date of earliest event reported
- March 24, 2025 (date) — Filing date of 8-K/A
- Malvern, PA (location) — Principal executive offices
FAQ
What is the purpose of this 8-K/A filing?
The purpose of this 8-K/A filing is to amend the previously filed 8-K report dated December 30, 2024, specifically concerning financial statements and exhibits.
When was the original 8-K filing made?
The original 8-K filing was made on December 30, 2024.
What is the filing date of this 8-K/A amendment?
This 8-K/A amendment was filed on March 24, 2025.
Where is Galera Therapeutics, Inc. headquartered?
Galera Therapeutics, Inc. is headquartered at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What is the SIC code for Galera Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Galera Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on March 24, 2025 regarding Galera Therapeutics, Inc. (GRTX).